Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

NCT01465802 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

236

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Dacomitinib
DRUG: Dacomitinib
DRUG: Doxycycline
DRUG: Probiotic
DRUG: Alclometasone cream

Sponsor

Pfizer